...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Message: Resverlogix needs to host another R&D Day for Investors and Analysts

It's been ~21 months since Resverlogix hosted an Research and Development day for Investors and Analysts. With BETonMACE finishing by end of year (according to most recent company guidance), the time is right for another R&D day in my opinion. The last ones were Sept 2015 (before BETonMACE began) and October 2016 (~21 months ago). I was reminded of this by Esperion's R&D Day announcement today.


New Message
Please login to post a reply